H.C. Wainwright Sticks to Their Buy Rating for Microbot Medical Inc (MBOT)

By Carrie Williams

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Microbot Medical Inc (MBOTResearch Report) today and set a price target of $10. The company’s shares closed last Monday at $5.42.

Selvaraju observed:

“Our price target is derived from an estimated market value of the firm at $60M, which includes a discounted cash flow (DCF)-based asset value of SCS, assuming 60% probability of approval, 20% discount rate and 2% terminal growth rate.”

According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.7% and a 27.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.

Currently, the analyst consensus on Microbot Medical Inc is a Moderate Buy with an average price target of $10.

See today’s analyst top recommended stocks >>

The company has a one-year high of $19.40 and a one-year low of $1.38. Currently, Microbot Medical Inc has an average volume of 44.44K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Microbot Medical, Inc. is a pre-clinical medical device company, which engages in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms.